$CLOV

Soares Karen sold $233K of CLOV

Soares Karen (Chief Legal Officer) sold 51,700 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.51 ($0.23M total) on 2026-07-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soares Karen
Published Jul 20, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
medium confidence
Mentioned
$CLOV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The disclosure provides incremental information about insider liquidity and planned selling, but it does not include new business, regulatory, or financial developments.

02

Market read

Traders may treat this as a low-signal datapoint for sentiment, not a standalone catalyst.

03

What to watch

The presence of a 10b5-1 plan means the sale timing is pre-set, which can weaken the signal-to-noise for interpreting bearish intent.

Relevance 3/10Novelty 5/10Timing: Filed same day as the 2026-07-20 sale date.

Background

The filing is an SEC Form 4 insider transaction by CLOV’s Chief Legal Officer, reported as an open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$CLOVNeutralMedium confidence
Context

Clover Health CLOV disclosed an officer open-market sale of 51,700 shares at $4.51 on 2026-07-20 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely muted unless paired with other new company-specific news.

Evidence & confidence

Form 4 shows an officer sale (not a purchase) and includes a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider selling can still coincide with near-term risk perception, so traders may watch for follow-on disclosures or changes in trading patterns.

Key entities

  • Clover Health Investments, Corp. /DE

    Subject of the Form 4 insider transaction disclosure.

  • Soares Karen

    Chief Legal Officer who sold 51,700 shares at $4.51 on 2026-07-20 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLOVHigh

Why is Clover Health stock climbing 4% today?

Clover Health (CLOV) stock rose 4.3% in pre-market trading after Needham initiated coverage with a Buy rating and $6.00 price target, citing its Medicare Advantage rating and cohort economics. The company's upcoming conference presentation and Q3 earnings report also contributed to the positive sentiment. The Nasdaq Composite was up 0.5% in pre-market.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.

$CLOVHigh

Why Is Clover Health (CLOV) Stock Soaring Today

Clover Health (CLOV) stock rose 10.7% premarket after CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The ratings, excluding disputed measures, boost payments and enrollment. Shares later cooled to $4.81, up 5%. CLOV is up 99.5% YTD but still below its 52-week high.

$CLOVMed

Is Clover Health Stock Too Dependent On One Group Of Members?

Clover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.

$CLOVMed

Clover Health Medicare Advantage PPO Plans Earn 5-Star Rating; HMO at 4.5 Stars

Clover Health's PPO Medicare Advantage plans received a 5.0 Star rating and HMO plans 4.5 Stars for 2027, impacting 2028 payments. CMS removed 20 measures for PPO plans, raising their rating. Clover's MA membership grew ~48% YoY to >157,000 members, with 98% in PPO plans. The company ranked #1 among non-SNP PPO plans with >2,000 members on core HEDIS measures, scoring 4.82 out of 5.